Satellos Bioscience Inc.
MSCLF
$0.49
$0.00-0.10%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.92M | 15.32M | 14.45M | 14.31M | 13.00M |
| Gross Profit | -16.92M | -15.32M | -14.45M | -14.31M | -13.00M |
| SG&A Expenses | 7.47M | 6.81M | 6.21M | 5.99M | 6.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.39M | 22.13M | 20.65M | 20.30M | 19.31M |
| Operating Income | -24.39M | -22.13M | -20.65M | -20.30M | -19.31M |
| Income Before Tax | -21.82M | -22.64M | -21.49M | -20.54M | -20.98M |
| Income Tax Expenses | 114.00K | 95.00K | 63.00K | -- | -- |
| Earnings from Continuing Operations | -21.93 | -22.74 | -21.55 | -20.54 | -20.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.93M | -22.74M | -21.55M | -20.54M | -20.98M |
| EBIT | -24.39M | -22.13M | -20.65M | -20.30M | -19.31M |
| EBITDA | -24.38M | -22.12M | -20.64M | -20.29M | -19.31M |
| EPS Basic | -0.14 | -0.16 | -0.17 | -0.18 | -0.19 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | -0.10 | -0.10 |
| EPS Diluted | -0.14 | -0.16 | -0.17 | -0.18 | -0.19 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 624.89M | 570.58M | 512.15M | 459.11M | 451.41M |
| Average Diluted Shares Outstanding | 624.89M | 570.58M | 512.15M | 459.11M | 451.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |